Provided by Tiger Trade Technology Pte. Ltd.

Tempus AI

76.50
-5.4000-6.59%
Pre-market: 77.400.9000+1.18%04:39 EDT
Volume:7.18M
Turnover:561.21M
Market Cap:13.89B
PE:-53.36
High:82.81
Open:81.98
Low:75.92
Close:81.90
52wk High:104.32
52wk Low:40.77
Shares:181.56M
Float Shares:115.00M
Volume Ratio:0.99
T/O Rate:6.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4337
EPS(LYR):-1.4100
ROE:-67.44%
ROA:-8.55%
PB:31.22
PE(LYR):-54.26

Loading ...

Tempus Publishes Investor Deck on Planned Personalis Acquisition to Expand MRD Testing Platform

Reuters
·
Jul 20

Sector Update: Healthcare

MT Newswires Live
·
Jul 20

Tempus AI Falls 8% in Pre-Market Trading, Acquisition of Personalis Sparks Market Concerns Over Cash Deployment

Market Focus
·
Jul 20

Tempus AI Shares Fall 8.5% Premarket After Co to Acquire Personalis in $1.5 Bln Deal

THOMSON REUTERS
·
Jul 20

Tempus to Acquire Personalis for $1.5 Billion

Reuters
·
Jul 20

Tempus AI to acquire Personalis for $16.25 per share

TIPRANKS
·
Jul 20

Tempus AI Agrees to Buy Personalis for USD 16.25 Per Share in USD 1.5 Billion Deal

Reuters
·
Jul 20

Tempus AI Inc - Maximum Exchange Ratio Set at 0.3356 Tempus AI Shares Per Personalis Share

THOMSON REUTERS
·
Jul 20

Tempus - Consideration Structured as 100% Stock, Cash Option Capped at 50%

THOMSON REUTERS
·
Jul 20

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (mrd) into Its Ai-enabled Precision Oncology Platform

THOMSON REUTERS
·
Jul 20

Tempus AI Inc - Cash Consideration Will be Financed with Cash on Hand and Borrowings Under Company's Then Existing Credit Facilities

THOMSON REUTERS
·
Jul 20

Dimon Warns AI Risks

AI Industry Frontlines
·
Jul 17

How Do Tempus AI’s (TEM) NHS Prostate Results Shape Its Clinical Credibility Narrative?

Simply Wall St.
·
Jul 17

AI Trading Has Become a 'Rubber Band,' Goldman Sachs Top Trader: The Question is 'When Will It Snap'

AI Industry Frontlines
·
Jul 17

AI Market Outlook; The Era Of Risk-Free Gains Has Come To An End

AI Industry Frontlines
·
Jul 17

Movement Alert|Tempus AI Falls 5.17% in Regular Trading, Partnership Termination and Executive Share Reduction Continue to Weigh on Stock

Market Focus
·
Jul 17

Tempus Cites Real-world UK NHS Study Showing Prostate Pathology AI Changes Diagnosis in 5% of Cases

Reuters
·
Jul 16

Tempus AI is Maintained at Buy by Guggenheim

Dow Jones
·
Jul 16

Tempus AI price target raised to $71 from $68 at TD Cowen

TIPRANKS
·
Jul 15

Movement Alert|Tempus AI Rises 5.19% in Regular Trading, Trading at $58.755

Market Focus
·
Jul 15